Logo image of RCKT

ROCKET PHARMACEUTICALS INC (RCKT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RCKT - US77313F1066 - Common Stock

3.39 USD
-0.06 (-1.74%)
Last: 12/12/2025, 8:00:01 PM
3.5 USD
+0.11 (+3.24%)
After Hours: 12/12/2025, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, RCKT scores 2 out of 10 in our fundamental rating. RCKT was compared to 531 industry peers in the Biotechnology industry. Both the profitability and financial health of RCKT have multiple concerns. RCKT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RCKT has reported negative net income.
RCKT had a negative operating cash flow in the past year.
RCKT had negative earnings in each of the past 5 years.
RCKT had a negative operating cash flow in each of the past 5 years.
RCKT Yearly Net Income VS EBIT VS OCF VS FCFRCKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of RCKT (-65.46%) is worse than 60.64% of its industry peers.
With a Return On Equity value of -76.80%, RCKT perfoms like the industry average, outperforming 53.67% of the companies in the same industry.
Industry RankSector Rank
ROA -65.46%
ROE -76.8%
ROIC N/A
ROA(3y)-44.2%
ROA(5y)-38.05%
ROE(3y)-50.34%
ROE(5y)-43.19%
ROIC(3y)N/A
ROIC(5y)N/A
RCKT Yearly ROA, ROE, ROICRCKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCKT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCKT Yearly Profit, Operating, Gross MarginsRCKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for RCKT has been increased compared to 1 year ago.
The number of shares outstanding for RCKT has been increased compared to 5 years ago.
The debt/assets ratio for RCKT is higher compared to a year ago.
RCKT Yearly Shares OutstandingRCKT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
RCKT Yearly Total Debt VS Total AssetsRCKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -2.78, we must say that RCKT is in the distress zone and has some risk of bankruptcy.
RCKT has a Altman-Z score (-2.78) which is comparable to the rest of the industry.
RCKT has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
RCKT has a worse Debt to Equity ratio (0.06) than 61.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -2.78
ROIC/WACCN/A
WACCN/A
RCKT Yearly LT Debt VS Equity VS FCFRCKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

RCKT has a Current Ratio of 7.30. This indicates that RCKT is financially healthy and has no problem in meeting its short term obligations.
RCKT has a better Current ratio (7.30) than 71.19% of its industry peers.
A Quick Ratio of 7.30 indicates that RCKT has no problem at all paying its short term obligations.
The Quick ratio of RCKT (7.30) is better than 71.37% of its industry peers.
Industry RankSector Rank
Current Ratio 7.3
Quick Ratio 7.3
RCKT Yearly Current Assets VS Current LiabilitesRCKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

RCKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.27%, which is quite good.
EPS 1Y (TTM)19.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RCKT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.65% yearly.
RCKT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 473.92% yearly.
EPS Next Y22.11%
EPS Next 2Y18.97%
EPS Next 3Y14.87%
EPS Next 5Y11.65%
Revenue Next Year-100%
Revenue Next 2Y2606.84%
Revenue Next 3Y552.47%
Revenue Next 5Y473.92%

3.3 Evolution

RCKT Yearly Revenue VS EstimatesRCKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2024 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
RCKT Yearly EPS VS EstimatesRCKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RCKT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCKT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCKT Price Earnings VS Forward Price EarningsRCKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCKT Per share dataRCKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as RCKT's earnings are expected to grow with 14.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.97%
EPS Next 3Y14.87%

More info and screens

0

5. Dividend

5.1 Amount

RCKT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ROCKET PHARMACEUTICALS INC

NASDAQ:RCKT (12/12/2025, 8:00:01 PM)

After market: 3.5 +0.11 (+3.24%)

3.39

-0.06 (-1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners90.24%
Inst Owner Change0.71%
Ins Owners3.38%
Ins Owner Change29.06%
Market Cap366.87M
Revenue(TTM)N/A
Net Income(TTM)-240.91M
Analysts74.29
Price Target8.03 (136.87%)
Short Float %11.11%
Short Ratio4.58
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.36%
Min EPS beat(2)-3.91%
Max EPS beat(2)12.64%
EPS beat(4)3
Avg EPS beat(4)8.66%
Min EPS beat(4)-3.91%
Max EPS beat(4)15.34%
EPS beat(8)6
Avg EPS beat(8)8.37%
EPS beat(12)8
Avg EPS beat(12)6.49%
EPS beat(16)10
Avg EPS beat(16)4.34%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.07%
PT rev (3m)-0.61%
EPS NQ rev (1m)0.38%
EPS NQ rev (3m)-5.54%
EPS NY rev (1m)1.67%
EPS NY rev (3m)0.07%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.17
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)-2.22
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.87
OCFYN/A
SpS0
BVpS2.9
TBVpS2.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -65.46%
ROE -76.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.2%
ROA(5y)-38.05%
ROE(3y)-50.34%
ROE(5y)-43.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.01%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.3
Quick Ratio 7.3
Altman-Z -2.78
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)144.02%
Cap/Depr(5y)620.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.62%
EPS Next Y22.11%
EPS Next 2Y18.97%
EPS Next 3Y14.87%
EPS Next 5Y11.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y2606.84%
Revenue Next 3Y552.47%
Revenue Next 5Y473.92%
EBIT growth 1Y9.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.15%
EBIT Next 3Y10.6%
EBIT Next 5YN/A
FCF growth 1Y14.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.89%
OCF growth 3YN/A
OCF growth 5YN/A

ROCKET PHARMACEUTICALS INC / RCKT FAQ

What is the fundamental rating for RCKT stock?

ChartMill assigns a fundamental rating of 2 / 10 to RCKT.


What is the valuation status of ROCKET PHARMACEUTICALS INC (RCKT) stock?

ChartMill assigns a valuation rating of 0 / 10 to ROCKET PHARMACEUTICALS INC (RCKT). This can be considered as Overvalued.


How profitable is ROCKET PHARMACEUTICALS INC (RCKT) stock?

ROCKET PHARMACEUTICALS INC (RCKT) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ROCKET PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ROCKET PHARMACEUTICALS INC (RCKT) is expected to grow by 22.11% in the next year.